Search results
Results from the WOW.Com Content Network
Pregnant women with ITP are 1.83 times more likely to have bleeding episodes during pregnancy compared to non-pregnant females with ITP, however, with proper treatment, platelets rarely drop below 30,000. [63] In ITP, severe bleeding is a rare occurrence, and with treatment maternal deaths due to ITP are extremely rare. [63]
Rh o (D) immune globulin (RhIG) is a medication used to prevent RhD isoimmunization in mothers who are RhD negative and to treat idiopathic thrombocytopenic purpura (ITP) in people who are Rh positive. [2] It is often given both during and following pregnancy. [2] It may also be used when RhD-negative people are given RhD-positive blood. [2]
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
One common definition of thrombocytopenia requiring emergency treatment is a platelet count below 50,000/μL. [5] Thrombocytopenia can be contrasted with the conditions associated with an abnormally high level of platelets in the blood – thrombocythemia (when the cause is unknown), and thrombocytosis (when the cause is known).
Therapeutic plasma exchange (TPE) is a novel treatment for immune-mediated diseases and little research has been done for the effectiveness of TPE and patients with IMT. [15] TPE requires removing the patient's plasma which contains antibodies and replacing it with fluids such as sodium chloride , frozen plasma, packed red blood cells, and ...
Rozrolimupab is a recombinant antibody mixture, specifically containing 25 Rhesus D, or RhD, human antibodies, and is currently under development by Symphogen for the treatment of immune thrombocytopenic purpura (ITP) and for the prevention of hemolytic disease of the newborn (HDN). [1] [2]
Fostamatinib is a drug used to treat adults with low platelet count due to chronic immune thrombocytopenia (ITP) when a prior treatment for ITP has not worked well enough. Chronic immune thrombocytopenia is an autoimmune bleeding disorder where the blood doesn't clot as it should because of a low platelet count. [4] [6] [3]
Hetrombopag (also known as rafutrombopag; trade name Hengqu) is a pharmaceutical drug for the treatment of thrombocytopenia and anemia. [1] [2] [3]It is a non-peptide small‐molecule thrombopoietin receptor agonist.